GlassScriptPhysician profile
Scott Elder Bagenstose
NPI 1326000472
$23,019.43
in general payments reported to CMS, 2019-2025
41 companies · $6,043 in 2025
The $6,043 reported for 2025 was more than what 85% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,361 · 2020: $1,027 · 2021: $1,733 · 2022: $2,398 · 2023: $5,065 · 2024: $5,393 · 2025: $6,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $2,816 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,344 · Education: $334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,006.14 |
| Consulting Fee | $2,816.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,344.00 |
| Education | $334.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $6,256.67 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $3,475.45 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $2,038.93 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genentech USA, INC. | $1,901.38 | 2019-2025 | Xolair |
| Csl Behring | $1,483.93 | 2020-2025 | Hizentra, Haegarda, Andembry |
| Regeneron Healthcare Solutions, INC. | $1,453.33 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $1,040.39 | 2019-2025 | |
| Covis Pharma Gmbh | $704.61 | 2019-2023 | |
| Pfizer INC. | $583.78 | 2019-2025 | |
| Optinose US, INC. | $469.23 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $395.70 | 2021-2025 | Cuvitru, Takhzyro, Eohilia |
| Biocryst US Sales Co., LLC | $347.80 | 2021-2025 | Orladeyo |
| Grifols USA, LLC | $343.85 | 2019-2025 | Xembify, Prolastin-C Liquid, Gamunex-C |
| Sanofi-Aventis U.S. LLC | $342.68 | 2020-2025 | |
| Blueprint Medicines Corporation | $327.38 | 2022-2025 | Ayvakit |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Bagenstose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.